Table 3.

The prognostic significance of ABO blood type in different subgroups of ENKTL patients

Subgroup	5-year OS rate (%)		P
	Blood type O	Blood type non-O
Ann Arbor stage
I/II	66.1	53.2	0.002
III/IV	30.6	12.1	0.151
Treatment modality
CT combined RT	74.5	57.2	0.003
CT alone	37.7	30.2	0.158
RT alone	56.7	55.5	0.352
Chemotherapy regimen
Anthracyclines-containing	59.4	42.8	0.010
l-Asparaginase-containing	80.6	62.3	0.011

OS overall survival, CT chemotherapy, RT radiotherapy